Lifeward’s Earnings Call Balances Setbacks and Strategy

Lifeward Ltd. ((LFWD)) has held its Q1 earnings call. Read on for the main highlights of the call.

Lifeward’s latest earnings call painted a mixed picture, as management balanced clear strategic and financial progress with meaningful near-term setbacks. Investors heard an upbeat tone around acquisitions, cash strengthening and ReWalk growth, but this was tempered by a 22% revenue drop, margin pressure and operational disruptions that will take until at least Q3 to fully resolve.

Strategic Acquisition of Oratech

Lifeward completed an equity-based acquisition of Oratech, gaining a protein oral delivery platform that includes the ORMD-0801 oral insulin program heading into Phase II. Management stressed the deal’s capital efficiency, noting it adds strategic upside without materially increasing operating expenses in the near term.

Strengthened Balance Sheet via Financing

The company shored up its balance sheet with a $10 million convertible note financing and roughly $6.5 million in cash acquired through the Oratech deal. As a result, unrestricted cash and equivalents jumped to $11.4 million from $2.2 million at the end of 2025, giving Lifeward more runway to navigate its operational transition.

ReWalk Sales Growth

ReWalk personal exoskeleton revenue rose 11% year over year to $1.6 million, up from $1.3 million, despite broader company headwinds. Management credited international strength, expanded reimbursement and distribution, including about 25% quarter-over-quarter growth in Germany, underscoring robust demand for the flagship platform.

Expanded Reimbursement and Distribution

Coverage gains from major Medicare Advantage providers, including Aetna, Humana and UnitedHealthcare, broadened access for ReWalk users. Alongside expanded domestic and international distribution, these wins position Lifeward’s neurorehabilitation portfolio for more durable, recurring growth as access and awareness improve.

Operating Expense Improvements (Non-GAAP)

Adjusted operating expenses fell 12% year over year to $5.9 million, down from $6.8 million, reflecting tighter cost control. The company cited better productivity in sales and marketing, lower reimbursement-related costs and reduced R&D after completing major programs as key drivers of this efficiency.

Stable Adjusted Loss and Lower Cash Burn

Despite the revenue decline, Lifeward kept its non-GAAP adjusted operating loss flat at $4.6 million compared with last year. Cash used in operating activities dropped 33% to $3.7 million versus Q1 2025, highlighting improved operational efficiency and working capital management during a challenging quarter.

New Upper Body Exoskeleton Initiative

Lifeward also acquired an upper body exoskeleton technology aimed at roughly 4.6 million stroke survivors, broadening its rehab footprint. Development work toward commercialization is underway, and management described the device as a natural complement to the existing ReWalk platform.

Quarterly Revenue Decline

Total Q1 2026 revenue slipped to $3.9 million from $5.0 million a year earlier, a decline of about 22%. The drop was primarily tied to reduced AlterG shipments caused by temporary supply chain constraints and working capital issues, rather than demand weakness, according to management.

Gross Margin Compression

Gross margin fell to 34.2% from 42.2%, an approximately 800 basis-point decline that weighed on profitability. Management said 75% to 85% of the pressure came from unfavorable foreign exchange and tariffs, with the rest tied to lower manufacturing absorption as volumes fell.

Higher GAAP Operating Loss from One-Time Charge

GAAP operating loss widened to $10.3 million, driven largely by a one-time noncash R&D and intangible asset expense of about $4.9 million linked to Oratech. While the charge is nonrecurring, it magnified the reported loss and may concern investors focused on near-term profitability.

Manufacturing Transition and Supply Disruption

Lifeward’s closure of its Fremont facility and shift to contract manufacturing in Massachusetts created meaningful disruption. Facility moves and sourcing constraints caused timing issues and temporary AlterG shipment delays, which in turn hurt revenue and reduced factory utilization.

Tariffs and FX Headwinds

Tariffs and adverse foreign currency movements were another acute drag, contributing the majority of the gross margin decline. These external headwinds compounded the impact of lower production volumes and highlight Lifeward’s sensitivity to global trade and currency dynamics.

Execution Risk on AlterG Backlog

Management emphasized a secured backlog of AlterG orders and expects shipments to catch up across Q2 and Q3. However, they cautioned that some issues may linger into Q2, implying execution risk and leaving investors reliant on flawless operational follow-through for revenue recovery.

Lack of Formal 2026 Revenue Guidance

The company is informally targeting full-year revenue similar to 2025 but declined to issue formal 2026 guidance. That stance reflects uncertainty around the timing of shipment normalization and manufacturing transition, signaling that visibility remains limited despite management’s confidence.

Forward-Looking Outlook and Path to Profitability

Looking ahead, Lifeward expects the Q1 revenue shortfall to be largely offset as AlterG backlog ships through Q2 and potentially Q3, with a clearer setup beyond that. Management pointed to ReWalk growth, cost cuts, improved liquidity and lower cash burn as building blocks for a path to profitability into late 2026 or 2027, while acknowledging ongoing execution risk.

Lifeward’s earnings call ultimately framed a company in transition, balancing short-term pain against long-term opportunity. Investors will be watching closely to see if management delivers on shipment recovery, stabilizes margins and converts its stronger balance sheet and new assets into sustainable growth and eventual profits.